» Articles » PMID: 35317237

Multi-omics Landscape and Clinical Significance of a -driven Immune Signature: Implications for Risk Stratification and Frontline Therapies in Pancreatic Cancer

Overview
Specialty Biotechnology
Date 2022 Mar 23
PMID 35317237
Authors
Affiliations
Soon will be listed here.
Abstract

mutation was recently implicated in promoting invasion and poor prognosis of pancreatic cancer (PACA) by regulating the tumor immune microenvironment. However, -driven immune landscape and clinical significance remain elusive. In this study, we applied the consensus clustering and weighted correlation network analysis (WGCNA) to identify two heterogeneous immune subtypes and immune genes. Combined with -driven genes determined by mutation status, a -driven immune signature (SDIS) was developed in ICGC-AU2 (microarray data) via machine learning algorithm, and then was validated by RNA-seq data (TCGA, ICGC-AU and ICGC-CA) and microarray data (GSE62452 and GSE85916). The high-risk group displayed a worse prognosis, and multivariate Cox regression indicated that SDIS was an independent prognostic factor. In six cohorts, SDIS also displayed excellent accuracy in predicting prognosis. Moreover, the high-risk group was characterized by higher frequencies of / mutations and deletion, superior immune checkpoint molecules expression and more sensitive to chemotherapy and immunotherapy. Meanwhile, the low-risk group was significantly enriched in metabolism-related pathways and suggested the potential to target tumor metabolism to develop specific drugs. Overall, SDIS could robustly predict prognosis in PACA, which might serve as an attractive platform to further tailor decision-making in chemotherapy and immunotherapy in clinical settings.

Citing Articles

Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning.

Zhang X, Lin F, Wen Y, Guan K Discov Oncol. 2025; 16(1):96.

PMID: 39873820 PMC: 11775367. DOI: 10.1007/s12672-025-01841-8.


Predicting Pancreatic Cancer in New-Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large-Scale Prospective Cohort Study.

Sun Y, Hu C, Hu S, Xu H, Gong J, Wu Y Cancer Med. 2024; 13(21):e70388.

PMID: 39526476 PMC: 11551786. DOI: 10.1002/cam4.70388.


Immune perturbation network identifies an EMT subtype with chromosomal instability and tumor immune-desert microenvironment.

Xu H, Fu X, Liu B, Weng S, Guo C, Quan L iScience. 2023; 26(10):107871.

PMID: 37766999 PMC: 10520355. DOI: 10.1016/j.isci.2023.107871.


SMAD Proteins in TGF-β Signalling Pathway in Cancer: Regulatory Mechanisms and Clinical Applications.

Wang Q, Xiong F, Wu G, Wang D, Liu W, Chen J Diagnostics (Basel). 2023; 13(17).

PMID: 37685308 PMC: 10487229. DOI: 10.3390/diagnostics13172769.


Systematic analysis of transcriptome signature for improving outcomes in lung adenocarcinoma.

Ge X, Xu H, Weng S, Zhang Y, Liu L, Wang L J Cancer Res Clin Oncol. 2023; 149(11):8951-8968.

PMID: 37160628 DOI: 10.1007/s00432-023-04814-y.


References
1.
Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

2.
Liu Z, Liu L, Lu T, Wang L, Li Z, Jiao D . Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. J Oncol. 2021; 2021:6664386. PMC: 7846409. DOI: 10.1155/2021/6664386. View

3.
Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

4.
Deo R . Machine Learning in Medicine. Circulation. 2015; 132(20):1920-30. PMC: 5831252. DOI: 10.1161/CIRCULATIONAHA.115.001593. View

5.
Li J, Yuan S, Norgard R, Yan F, Sun Y, Kim I . Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Cancer Discov. 2020; 11(3):736-753. PMC: 7933070. DOI: 10.1158/2159-8290.CD-20-0519. View